What are the side effects of lurbinectedin for lung cancer?

Lurbinectedin side effects reported in lung cancer patients

Lurbinectedin is approved for adults with metastatic small-cell lung cancer that has progressed after platinum-based chemotherapy. The most frequent side effects involve bone marrow suppression and gastrointestinal upset.

Common side effects

- Neutropenia occurs in roughly 80% of patients, with severe (grade 3-4) cases in about 50%.
- Thrombocytopenia affects roughly 50% of patients, with severe events in 10%.
- Anemia develops in 50-60% of patients, with severe cases in 10-15%.
- Fatigue is reported by 60-70% of patients and can be grade 3 or higher in up to 10%.
- Nausea and vomiting occur in 40-50% of patients; nausea is more common than vomiting.
- Constipation, diarrhea, and decreased appetite each affect 20-40% of patients.
- Elevated liver enzymes (ALT/AST) occur in 30-40% of patients, usually mild to moderate.

Less common but serious side effects

- Febrile neutropenia requiring hospitalization occurs in 5-10% of patients.
- Severe infections secondary to neutropenia develop in roughly 5%.
- Rhabdomyolysis has been observed in fewer than 1% of patients, prompting creatine kinase monitoring.
- Myelosuppression can delay or reduce subsequent doses in up to 30% of patients.
- Hypersensitivity reactions are rare but can include rash or infusion reactions.

How long do side effects last?

Most hematologic toxicities peak within the first two weeks after each dose and recover by day 21. Nausea and fatigue may persist between cycles in some patients. Liver enzyme elevations typically resolve within two weeks of holding or reducing the dose.

Dose adjustments for side effects

The starting dose is 3.2 mg/m² every 21 days. Neutropenia, thrombocytopenia, or grade 3-4 non-hematologic toxicity triggers a 20-25% dose reduction for the next cycle. Permanent discontinuation is recommended if grade 4 non-hematologic toxicity recurs after two reductions.

Who is at higher risk?

Patients with prior radiation to the chest, extensive prior chemotherapy, or baseline liver impairment experience more severe myelosuppression. Older adults and those with poor performance status also show higher rates of dose delays.

What monitoring is required?

Complete blood counts are checked before each cycle and on day 8-14 of the first cycle. Liver function tests are obtained before every dose. Patients are advised to report fever above 100.4 °F promptly.

How does lurbinectedin compare with topotecan?

Topotecan produces similar rates of severe neutropenia but higher rates of anemia and alopecia. Lurbinectedin shows lower rates of alopecia and diarrhea, but comparable fatigue and nausea. Both agents require growth-factor support in a subset of patients.

What patient questions arise most often?

Patients frequently ask whether hair loss is expected; alopecia occurs in fewer than 10% of lurbinectedin recipients. Others inquire about long-term lung toxicity; no cases of interstitial lung disease have been reported in trials.